Relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.
LowStandard timeline
Low Cost
Effective:2025-06-20
Enforcing Agencies
Health and Human Services Commission (HHSC)
01
Compliance Analysis
Key implementation requirements and action items for compliance with this legislation
Implementation Timeline
Effective Date: June 20, 2025 (Immediate effect).
Compliance Deadline:Q4 2025. While the state's report is due October 1, 2026, vendors servicing state contracts should expect data calls regarding inventory and distribution demographics starting late 2025 to allow for agency aggregation.
Agency Rulemaking: The statute does not explicitly mandate formal rulemaking, but HHSC must internally define "saturation goals" and "insufficiency" methodologies prior to the 2026 reporting cycle.
Immediate Action Plan
Audit Data Capabilities: Immediately verify if your logistics software can generate reports on distribution density by zip code/county to preemptively answer HHSC data calls.
Review Contract Terms: Check current government contracts for data-sharing obligations to ensure you are not caught off guard by a request for "program funding and resources" data.
Monitor Procurement Portals: Watch for new RFPs in late 2026 that will be issued to address the "supply insufficiencies" identified in the first report.
Operational Changes Required
Contracts
Current State Vendors: Review Master Services Agreements (MSAs) with HHSC and public universities. Expect administrative requests under "cooperation" or "audit" clauses to provide data on distribution locations and volume.
Future RFPs: The "Statewide Saturation Goal" established by this report will dictate volume requirements for future solicitations. Vendors should align proposal metrics with the "insufficiencies" identified in the inaugural report.
Hiring/Training
No new hiring or certification is required.
Reporting & Record-Keeping
Granular Data Segmentation: Vendors distributing opioid antagonists on behalf of the state must ensure their data systems can track and report distribution by:
Geographic location (specifically identifying rural vs. urban saturation).
End-user demographics (if applicable under current privacy laws).
Methodology Alignment: Prepare to disclose the methodology used to track inventory to ensure it integrates with HHSC’s reporting format.
Fees & Costs
No new fees or direct costs are imposed on the private sector.
Strategic Ambiguities & Considerations
The statute requires HHSC to determine a "Statewide Saturation Goal" and identify "Insufficiencies in Current Supply," but fails to define the metrics for either.
The Risk: If HHSC defines "saturation" conservatively, state procurement volumes may plateau. If defined aggressively (e.g., per-capita vs. per-overdose), procurement volume will increase.
The Watch: Monitor HHSC announcements for Requests for Information (RFI) regarding how "saturation" should be calculated. This definition determines the Total Addressable Market (TAM) for state-purchased antagonists.
Need Help Understanding Implementation?
Our government affairs experts can walk you through this bill's specific impact on your operations.
Information presented is for general knowledge only and is provided without warranty, express or implied. Consult qualified government affairs professionals and legal counsel before making compliance decisions.
The bill author has informed the committee that opioid antagonists are medications used to block the effects of opioids such as heroin and fentanyl and are effective for preventing overdose deaths. Current law requires the operation of a program to provide opioid antagonists for the prevention of opioid overdoses. Under that program, opioid antagonists may be provided to emergency medical services personnel, first responders, public schools, institutions of higher education, community centers, and other persons likely to be in a position to respond to an opioid overdose. H.B. 4783 would require a biennial report on opioid antagonist programs for opioid overdose reversal and prevention, which must include a needs assessment for the opioid antagonist program in current law and the development of certain goals, strategies, and recommendations, among other components.
CRIMINAL JUSTICE IMPACT
It is the committee's opinion that this bill does not expressly create a criminal offense, increase the punishment for an existing criminal offense or category of offenses, or change the eligibility of a person for community supervision, parole, or mandatory supervision.
RULEMAKING AUTHORITY
It is the committee's opinion that this bill does not expressly grant any additional rulemaking authority to a state officer, department, agency, or institution.
ANALYSIS
H.B. 4783 amends the Health and Safety Code to require the Health and Human Services Commission (HHSC), not later than October 1 of each even-numbered year, to prepare a report evaluating the distribution of opioid antagonists in Texas to reverse and prevent opioid overdoses and submit the report to the governor, the lieutenant governor, and the speaker of the house of representatives. The bill defines "opioid antagonist" by reference as any drug that binds to opioid receptors and blocks or otherwise inhibits the effects of opioids acting on those receptors. The bill requires the report to do the following:
·include a needs assessment for the Department of State Health Services' (DSHS) opioid antagonist program;
·establish a statewide saturation goal for opioid antagonists and include a description of data sources and methodology used to estimate insufficiencies in the current supply of opioid antagonists and a communications plan to address opioid overdoses in areas of Texas at higher risk for increased numbers of overdoses;
·include a description of all state and federal money appropriated to the opioid antagonist program;
·establish opioid antagonist distribution strategies for Texas;
·list and describe all available state and federally funded purchase and distribution programs for opioid antagonists; and
·recommend improvements for addressing opioid overdoses among high-risk populations, including school-aged children, pregnant and postpartum women, and individuals residing in rural areas of Texas.
The bill requires HHSC, in preparing the report, to coordinate and consult with each state agency, institution of higher education, and political subdivision of Texas that receives funding or other resources under the DSHS opioid antagonist program for distribution of opioid antagonists.
HB4783 mandates the Health and Human Services Commission (HHSC) to establish statewide "saturation goals" for opioid antagonists, effectively defining the state's procurement strategy for the next biennium. While the direct reporting burden falls on state agencies, vendors and contractors in the pharmaceutical supply chain must prepare for granular data requests to support the state's mandatory "needs assessment. " Implementation Timeline Effective Date: June 20, 2025 (Immediate effect).
Q
Who authored HB4783?
HB4783 was authored by Texas Representative Gary Vandeaver during the Regular Session.
Q
When was HB4783 signed into law?
HB4783 was signed into law by Governor Greg Abbott on June 20, 2025.
Q
Which agencies enforce HB4783?
HB4783 is enforced by Health and Human Services Commission (HHSC).
Q
How urgent is compliance with HB4783?
The compliance urgency for HB4783 is rated as "low". Businesses and organizations should review the requirements and timeline to ensure timely compliance.
Q
What is the cost impact of HB4783?
The cost impact of HB4783 is estimated as "low". This may vary based on industry and implementation requirements.
Q
What topics does HB4783 address?
HB4783 addresses topics including alcoholism & drug abuse, crimes, crimes--drugs, state agencies, boards & commissions and health & human services commission.
Legislative data provided by LegiScanLast updated: November 25, 2025
Need Strategic Guidance on This Bill?
Need help with Government Relations, Lobbying, or compliance? JD Key Consulting has the expertise you're looking for.
